iZafe Group AB (publ) (IZAFE-B.ST)
SEK 0.21
(-0.93%)
SEK 0.21
(-0.93%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -35.63 Million SEK | -58.91% |
| 2022 | -23.4 Million SEK | 29.66% |
| 2021 | -33.27 Million SEK | -27.51% |
| 2020 | -26.09 Million SEK | -15.64% |
| 2019 | -22.56 Million SEK | -110.12% |
| 2018 | -10.73 Million SEK | -153.4% |
| 2017 | -4.23 Million SEK | 34.48% |
| 2016 | -6.46 Million SEK | -120.94% |
| 2015 | -2.92 Million SEK | 16.61% |
| 2014 | -3.51 Million SEK | 59.01% |
| 2013 | -8.56 Million SEK | -186.79% |
| 2012 | -2.98 Million SEK | 39.28% |
| 2011 | -4.91 Million SEK | 16.6% |
| 2010 | -5.89 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -4.56 Million SEK | -3.42% |
| 2024 Q1 | -5.56 Million SEK | 73.28% |
| 2024 Q2 | -4.01 Million SEK | 27.98% |
| 2023 Q1 | -5.05 Million SEK | 9.09% |
| 2023 Q3 | -5.01 Million SEK | 1.67% |
| 2023 Q2 | -5.09 Million SEK | -0.91% |
| 2023 Q4 | -20.84 Million SEK | -315.86% |
| 2023 FY | -37.19 Million SEK | -58.91% |
| 2022 Q2 | -5.18 Million SEK | 25.82% |
| 2022 FY | -23.4 Million SEK | 29.66% |
| 2022 Q3 | -5.68 Million SEK | -9.57% |
| 2022 Q1 | -6.98 Million SEK | 44.51% |
| 2022 Q4 | -5.55 Million SEK | 2.18% |
| 2021 Q2 | -7.96 Million SEK | -10.29% |
| 2021 Q4 | -12.59 Million SEK | -135.75% |
| 2021 Q1 | -7.21 Million SEK | 20.91% |
| 2021 FY | -33.27 Million SEK | -27.51% |
| 2021 Q3 | -5.34 Million SEK | 32.91% |
| 2020 Q2 | -5.1 Million SEK | 0.76% |
| 2020 Q1 | -5.13 Million SEK | 28.36% |
| 2020 Q4 | -9.12 Million SEK | -225.82% |
| 2020 FY | -26.09 Million SEK | -15.64% |
| 2020 Q3 | 7.25 Million SEK | 242.25% |
| 2019 Q2 | -6.34 Million SEK | -26.28% |
| 2019 FY | -22.56 Million SEK | -110.12% |
| 2019 Q3 | -4.02 Million SEK | 36.49% |
| 2019 Q4 | -7.17 Million SEK | -78.08% |
| 2019 Q1 | -5.02 Million SEK | -137.78% |
| 2018 Q2 | -3.97 Million SEK | -45.59% |
| 2018 FY | -10.73 Million SEK | -153.4% |
| 2018 Q1 | -2.73 Million SEK | -47.65% |
| 2018 Q3 | -1.91 Million SEK | 51.87% |
| 2018 Q4 | -2.11 Million SEK | -10.29% |
| 2017 Q2 | -799 Thousand SEK | -62.04% |
| 2017 Q3 | -1.09 Million SEK | -36.99% |
| 2017 Q4 | -1.85 Million SEK | -69.12% |
| 2017 FY | -4.23 Million SEK | 34.48% |
| 2017 Q1 | -493.07 Thousand SEK | -364.2% |
| 2016 Q3 | -839.95 Thousand SEK | 83.34% |
| 2016 FY | -6.46 Million SEK | -120.94% |
| 2016 Q2 | -5.04 Million SEK | -552.06% |
| 2016 Q1 | -773.2 Thousand SEK | -5.16% |
| 2016 Q4 | 186.63 Thousand SEK | 122.22% |
| 2015 Q4 | -735.28 Thousand SEK | 0.0% |
| 2015 Q2 | -728.54 Thousand SEK | 0.0% |
| 2015 Q1 | -728.54 Thousand SEK | 29.28% |
| 2015 FY | -2.92 Million SEK | 16.61% |
| 2015 Q3 | -735.28 Thousand SEK | -0.92% |
| 2014 FY | -3.51 Million SEK | 59.01% |
| 2014 Q4 | -1.03 Million SEK | -27.49% |
| 2014 Q2 | -808.42 Thousand SEK | 6.45% |
| 2014 Q1 | -864.18 Thousand SEK | 84.97% |
| 2014 Q3 | -808.08 Thousand SEK | 0.04% |
| 2013 Q3 | -409.04 Thousand SEK | 73.76% |
| 2013 FY | -8.56 Million SEK | -186.79% |
| 2013 Q4 | -5.75 Million SEK | -1306.1% |
| 2013 Q1 | -846.42 Thousand SEK | 25.59% |
| 2013 Q2 | -1.55 Million SEK | -84.21% |
| 2012 Q2 | -540.4 Thousand SEK | 32.81% |
| 2012 FY | -2.98 Million SEK | 39.28% |
| 2012 Q1 | -804.24 Thousand SEK | 0.0% |
| 2012 Q4 | -1.13 Million SEK | -125.36% |
| 2012 Q3 | -504.75 Thousand SEK | 6.6% |
| 2011 FY | -4.91 Million SEK | 16.6% |
| 2010 FY | -5.89 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AddLife AB (publ) | 585 Million SEK | 106.091% |
| Biotage AB (publ) | 376 Million SEK | 109.477% |
| Bonesupport Holding AB (publ) | 13.93 Million SEK | 355.815% |
| Doxa AB (publ) | 269.4 Million SEK | 113.228% |
| Elekta AB (publ) | 2.03 Billion SEK | 101.748% |
| Ortivus AB (publ) | -17.61 Million SEK | -102.334% |
| Ortivus AB (publ) | -17.61 Million SEK | -102.334% |
| Q-linea AB (publ) | -230.58 Million SEK | 84.546% |
| S2Medical AB (publ) | -15.26 Million SEK | -133.46% |
| Synsam AB (publ) | 696 Million SEK | 105.12% |